Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes

Grempler, 2012, Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors, Diabetes Obes Metab, 14, 83, 10.1111/j.1463-1326.2011.01517.x Gerich, 2010, Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications, Diabet Med, 27, 136, 10.1111/j.1464-5491.2009.02894.x List, 2009, Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes, Diabetes Care, 32, 650, 10.2337/dc08-1863 Ferrannini, 2012, SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects, Nat Rev Endocrinol, 8, 495, 10.1038/nrendo.2011.243 Häring, 2014, Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial, Diabetes Care, 37, 1650, 10.2337/dc13-2105 Häring, 2013, Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled trial, Diabetes Care, 36, 3396, 10.2337/dc12-2673 Kovacs, 2013, Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial, Diabetes Obes Metab, 16, 147, 10.1111/dom.12188 Roden, 2013, Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Diabetes Endocrinol, 1, 208, 10.1016/S2213-8587(13)70084-6 DeFronzo, 2012, The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia, Diabetes Obes Metab, 14, 5, 10.1111/j.1463-1326.2011.01511.x Baker, 2014, Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis, J Am Soc Hypertens, 8, 262, 10.1016/j.jash.2014.01.007 Chilton, 2015, Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes, Diabetes Obes Metab, 17, 1180, 10.1111/dom.12572 Cherney, 2014, Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus, Circ, 129, 587, 10.1161/CIRCULATIONAHA.113.005081 Muller, 2004, Am J Clin Nutr, 80, 1379, 10.1093/ajcn/80.5.1379 Heise, 2015, Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study, Clin Ther, 37, 793, 10.1016/j.clinthera.2014.12.018 Barnett, 2014, Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial, Lancet Diabetes Endocrinol, 2, 369, 10.1016/S2213-8587(13)70208-0 Ridderstrale, 2014, Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial, Lancet Diabetes Endocrinol, 2, 691, 10.1016/S2213-8587(14)70120-2 Rosenstock, 2014, Improved glucose control with weight loss, lower insulin doses and no increased hypoglycemia with empagliflozin added-on to titrated multiple daily injections of insulin in obese inadequately controlled patients with type 2 diabetes, Diabetes Care, 37, 1815, 10.2337/dc13-3055 Tikkanen, 2014, Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension, Diabetes Care, 33, 420 Wanner, 2016, Empagliflozin and progression of kidney disease in type 2 diabetes, N Engl J Med, 375, 323, 10.1056/NEJMoa1515920 Skrtic, 2014, Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration, Diabetol, 57, 2599, 10.1007/s00125-014-3396-4 Lytvyn, 2015, Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus, Am J Physiol Renal Physiol, 308, F77, 10.1152/ajprenal.00555.2014 Chino Y, Samukawa Y, Sakai S, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos 2014;35:391–404. Zinman, 2015, Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes, N Engl J Med, 373, 2117, 10.1056/NEJMoa1504720 2013, KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, Kidney Int, 3, 1 Ponikowski, 2016, 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC), Eur Heart J, 37, 2129, 10.1093/eurheartj/ehw128 Ferrannini, 2015, Energy balance following sodium-glucose co-transporter-2 inhibition, Diabetes Care, 38, 1730, 10.2337/dc15-0355